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remission (CR) cases since late 90´. Early concurrent radiation (RT) 
has been found as slightly beneﬁcial at cost of higher toxicity. This 
strategy has been used for regional treatment protocol since 2000 in 
VFN, University Hospital Prague.
Methods: The planned treatment consisted of 4 to 6 courses of plati-
num/etoposide chemotherapy (CT) and thoracic irradiation concomi-
tantly with the second and third cycle. RT dose 45 to 60 Gy with one 
daily fraction (1.8 - 2.0 Gy) in 5 to 6.5 weeks was prescribed. Patients 
with CR were assigned to PCI (30 Gy in 15 fractions) at the end of 
treatment. Survival, time to progression, local control, relapse pattern 
and toxicity data were collected. Possible prognostic factors as sex, 
age, concurrent RT yes or not, treatment response, PCI yes or not, were 
tested for survival impact.
Results: 53 consecutive patients were treated between Jan-2000 and 
Dec-2006, 31 men, 22 women, and median age 63 years (range 49 
- 80). CT in median dose of 5 cycles was predominantly cisplatin based 
(64%), RT in median dose of 55,8 Gy was given concurrently in 26 
(49%) of patients and sequentially in 19 (36%). Sequential strategy was 
preferred due to age over 70 or worse performance status. Thoracic RT 
was omitted in 8 patients, for poor performance status or progressive 
disease in 5 and due to radical surgery in 3 subjects. Esophagitis grade 
3-4 occurred in 43%, signiﬁcantly more often in concurrent RT (61% 
vs. 21%, p < 0.01). Early radiation pneumonitis of any grade occurred 
in 5%. Response rate (RR) 92% and CR 61% in concurrent group did 
not differ signiﬁcantly from sequential one (RR 89%, CR 53%). The 
median survival was 19 months and 3- and 5-year survival was 26% in 
all the patients. Survival differences in groups according to sex, age, 
partial versus complete treatment response or concurrent radiation 
delivery did not differ signiﬁcantly. Meaningful survival difference was 
observed between groups with PCI yes or not (3-and 5-year survival 
52% versus 18%), but without statistical signiﬁcance (p = 0.067). 
The median time to progression was 14 months for the whole group. 
Signiﬁcantly longer time to progression was in CR patients and PCI 
patients. Patterns of relapses were local only in 19%, distant with local 
progression 17%, distant only in 64%. Brain metastases were ﬁrst place 
of relapse in 13% of all patients (20% in non-PCI group) but none of 
18 (34%) PCI patients have had brain relapse. Intercurrent disease was 
cause of death in 7% of pts.
Conclusions: Concurrent early chemoradiotherapy in LD SCLC pa-
tients did not conﬁrm clear survival beneﬁt against sequential strategy 
in our group, probably for small number of subjects and high distant 
relapse rate, further investigation is warranted. PCI delivery has shown 
statistically signiﬁcant impact on time to progression and trend to lon-
ger overall survival and should be offered also to PR patients.
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Introduction: Preventive cranial irradiation (PCI) in patients (pts) 
with small-cell lung cancer (SCLC) decreases the overall rate of brain 
metastases, as shown by several randomized trials conducted in the 
1970s and 1980s. Results from retrospective data suggested a potential 
survival beneﬁt restricted to patients in complete remission. 
Purpose: To evaluate the effects of PCI on the rates of brain metasta-
ses and overall survival in patients with stage I-III SCLC after radical 
operations. 
Patients and methods: Since 2000, 40 pts with SCLC after radical 
operations were eligible for inclusion in a randomized trial. Their mean 
age was 57.01+1.05. The pts distribution by tumor extension was as 
follows: T1N0 - 1(2.5%), T2N0 - 2 (5.0%), T1N1 - 2 (5.0%), T2N1 - 7 
(17.5%), T3N0 - 1 (2.5%), T1N2 - 2 (5.0%), T2N2 - 15 (37.5%), T3N1 
- 3 (7.5%), T3N2 - 3 (7.5%), T4N2 - 2 (5.0%) and T2N3 - 2 (5.0%). 
After surgery all the pts were randomized to receive either 4 courses 
of adjuvant chemotherapy (ChT) including Cisplatin+VP-16 with PCI 
at a total dose of 30 Gy (a dose per fraction equal to 2 Gy) for 15 days, 
5 fractions per week (PCI group) or without PCI (control group). The 
interval between ChT courses was 3 weeks. For radiation treatment, the 
target volume was the whole brain. All the pts gave informed consent 
to participate. 20 pts were assigned to the PCI group and 20 to the 
control group. 16 (80.0%) pneumonectomies and 4 (20.0%) lobecto-
mies were perfomed in the control group. The respective ﬁgures in the 
PCI group were 15 (75.0%) and 5 (25.0%). No differences were found 
in the extent of tumor spread, its site, clinicoanatomical form and the 
affected side. 
Results: According to the data obtained, the overall rate of brain 
metastases for the pts in the control group was 15% vs 0.0%for the 
pts in the PCI group. In no case CT detected any changes in the brain 
structures. Two-year follow-up of the pts without signs of metastatic 
involvement of the brain after irradiation found no abnormalities in the 
neurological status. Overall two-year survival was 67.5+10.1%, this 
rate in the PCI and control groups being 66.7+14.6% I 62.9+14.5% 
respectively. 
Conclusions: The evidence provided suggests that surgery with 
adjuvant chemotherapy and PCI decreases the overall rate of brain 
metastases in SCLC. 
SCLC: Cytotoxic Chemotherapy
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Option: Intensiﬁed treatment should be a rational treatment option in 
SCLC with respect to the pronounced sensitiviy to chemotherapy in 
primary treatment. However, convincing results have not been pre-
sented, so intensiﬁed treatment is not used routinely.
Background: Many studies have compared intensiﬁed, dose-dense and 
higher dose and multiple drug treatment with standard treatment. The 
results differ and e.g. high dose with stem cell rescue has not been a 
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success. However, a comprehension of 21 randomised studies demon-
strated that intensiﬁed treatment is superior to standard in many studies, 
indicating the need of further studies (Tjan-Hejnen et al. Annals of 
Oncology (2002)13(10):1519).
Besides, what might happen if dose-dense treatment, higher doses and 
an extra drug were given at the same time? Is it possible to give? We 
started such a study six years ago but because of slow inclusion rate af-
ter 3 years, the study was stopped. Now we have evaluated the results.
Materials and methods. Our standard treatment (S) consisted of 6 
courses with carboplatin, 5 AUC and etoposide 100 mg/m2 iv day 1-3 
with 3 weeks interval. Thoracic radiotherapy was given 1.5 Gy bid to 
45 Gy to patients with LD, starting at course two. The intensiﬁed treat-
ment (I) consisted of carboplatin 6 AUC, etoposide 120 mg/m2 and Ifos-
famide 5000 mg/m2 course 1 and 3000 mg/m2 in course 2-6. Treatment 
was given with 2 weeks interval, and Neupogen was given to make 
avoid leucopenia. Radiotherapy was given in the same way as in S. 
Results: Two year survival was 5/7 (72%) in I and 4/11 (37%) in S. 
Five year survival was 4/7 (57%) in I and 3/11 (27%) in S. Now, after 
more than 5 years 4/7 are still alive in I and 2/11 (18%) in S. Trombocy-
topenia and fatigue was a greater problem in I, but leucopenia was not. 
Conclusion: We ﬁnd the results promising but not verifying a value 
of intensiﬁed treatment since there were too few patients to make the 
differences signiﬁcant. Therefore we plan to start a multicentric phase 
III study with the same treatment arms and with two year survival as 
the primary endpoint. Since we have a limited number of patients with 
SCLC, LD in Sweden we are very interested to come in contact with 
other groups, interested to test this option.
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Background: Small cell lung cancer (SCLC) is an aggressive malig-
nancy. The prognosis for the patients is very poor with metastases often 
present at the time of diagnosis. Despite the initial chemo-sensitivity 
the majority of the patients will relapse and die of their disease. Patient 
with Extensive Disease (ED) have a disappointing survival of 8-12 
weeks without chemotherapy and 8-11 months after proper treatment. 
Irinotecan, a topoisomerase I inhibitor, has been reported as an active 
new agent in SCLC. In combination with cisplatin, it has showed supe-
riority in response rates and progression free survival over the standard 
regimen of cisplatin and etoposide. We conducted a phase II study in 
order to evaluate the efﬁcacy and safety of Carboplatin, Irinotecan and 
Etoposide (CIE) combination in extensive-disease SCLC (ED-SCLC)
Patients and Methods: Forty six chemo-naïve patients with ED-SCLC 
and PS 0-2 were enrolled. Forty of them were men and 6 women. All of 
them were smokers and the median age was 59.6 years. We admin-
istered carboplatin AUC 5 on day 1, irinotecan 120/m2 on day 2 and 
etoposide 75mg/m2 on days 1,2,3 in a 21 days repeated cycles. The 
treatment was continued for up to 6 cycles. Response assessments were 
performed after cycles 3 and 6 and every 2 months subsequently. The 
patients were evaluated for response, survival and toxicity. Clinical (as 
site of metastasis) and laboratory (such as LDH) parameters were tested 
as prognostic factors for survival.
Results: Two hundred and two cycles were administered with an aver-
age of 4.5 cycle per patient. Overall response rate was 52.2% (partial 
and complete), mean overall survival was 16.3 months (CI: 95%: 13.0-
19.7) and there was an1 year survival rate of 43.47%.
Patients with brain metastasis had worse prognosis (P: 0.004). 
The three drug regimen was well tolerated. Only 1 patient had diarrhea 
grade II, 6 had grade III/IV and 1 patient was referred with abdominal 
pain. One was presented with fatal thrombocytopenia while two toxic 
deaths were reported. Nine patients (19.5%) had neutropenia grade 
III/IV, without being fatal, and 3 were presented with grade III anemia 
which need blood transfusions.
Conclusion: CIE regimen is effective and well tolerated for the treat-
ment of the poor prognosis group of ED-SCLC patients
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There is no reference second-line treatment for small-cell lung cancer 
(SCLC). The vital prognosis of these patients is poor and special atten-
tion must thus be paid both to quality of life and to economic issues. 
The aim of this phase II randomized trial (GFPC0501) is to compare, 
in patients with progressive SCLC after ﬁrst-line platinum-based che-
motherapy, oral multidrug chemotherapy (CCNU, cyclophosphamide, 
etoposide) and classical intravenous therapy with cyclophophamide, 
doxorubicine and vincristine (CAV regimen) in terms of tolerability, 
efﬁcacy (response rate, median one-year and overall survival times), 
quality of life and healthcare consumption. Based on a two-stage Briant 
and Day approach, the study will require a total of 138 patients, and the 
ﬁrst 38 patients will be included in an interim analysis. 
At this time, 41 had been enrolled by 16 centers (21 on oral multidrug 
therapy and 19 on CAV regimen).The results of the interim analysis 
will be available in June 2007 for a presentation at the IASCL meeting.
ClinicalTrials.gov: NCT00418743; 
supported by a grant of AMGEN France, Baxter, UCB.
